Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets

This study has been completed.
Sponsor:
Information provided by:
Sandoz
ClinicalTrials.gov Identifier:
NCT00946504
First received: July 24, 2009
Last updated: March 27, 2017
Last verified: July 2009
  Purpose
To demonstrate the relative bioequivalency comparing Geneva's 10 mg Glipizide tablets to Roerig's 10 mg Glucotrol tablets.

Condition Intervention Phase
Type 2 Diabetes
Drug: Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
Drug: Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Two-Way Crossover Bioequivalence Study Comparing Single 10 mg Doses of Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets

Resource links provided by NLM:


Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence based on AUC and Cmax [ Time Frame: 9 days ]

Enrollment: 28
Study Start Date: October 1992
Study Completion Date: October 1992
Primary Completion Date: October 1992 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
Drug: Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
Active Comparator: 2
Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
Drug: Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00946504

Sponsors and Collaborators
Sandoz
Investigators
Principal Investigator: Roger D. Anderson, M.D. Biodecision, Inc.
  More Information

Responsible Party: Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc.
ClinicalTrials.gov Identifier: NCT00946504     History of Changes
Other Study ID Numbers: 9208525-G2
Study First Received: July 24, 2009
Last Updated: March 27, 2017

Additional relevant MeSH terms:
Glipizide
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 28, 2017